Ask AI
ProCE Banner Series

Congress to Clinic: Continual Evolution of HER3-Targeting in NSCLC With Expert Perspectives on Clinical Advances and Practical Application

Join us online for this live 60-minute, CME-certified webinar to hear from experts about the latest clinical breakthroughs and insights on the practical application of HER3-targeted therapies for patients with NSCLC. During this live meeting, you will have the opportunity to interact with an expert and ask questions at the end of the session. Register today!

To Register: Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  AMA
Who Should Attend

This program is intended for thoracic oncologists, medical oncologists, and other healthcare professionals caring for patients with lung cancer.

All Events

Congress to Clinic: Continual Evolution of HER3-Targeting in NSCLC With Expert Perspectives on Clinical Advances and Practical Application

Past Events

November

20

2023

1:00 PM - 2:00 PM Eastern Time (ET)

Virtual

Topics

Welcome and Introduction

Brief Overview of Recent Advances in ADCs in Lung Cancer

Exploring Recent Advances in Targeting HER3 in NSCLC

  • HER3 as a Therapeutic Target
  • Unpacking the Potential of HER3-Targeted Therapy
  • Safety Considerations With HER3-Targeted Agents

Audience Question and Answer Session

Final Thoughts

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC) 

Target Audience
This program is intended for thoracic oncologists, medical oncologists, and other healthcare professionals caring for patients with lung cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate recently presented data on HER3-directed therapies, as appropriate and guided by expert recommendations, to optimize care for patients with NSCLC.
  • Prepare strategies for effective identification and management of AEs associated with HER3-directerd therapies considering pharmacologic activity and clinical safety data.
  • Interpret emerging data on novel HER3-directed therapies for patients with cancer to aid optimal integration into practice.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Daiichi Sankyo, Inc.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191